PREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DM

Sponsor
Universiti Sains Malaysia
Study ID
NCT07795918
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Study Details

The goal of this observational study is to learn whether community pharmacy-based risk assessment and point-of-care HbA1c testing can help detect undiagnosed type 2 diabetes and prediabetes among adults in Irbid Governorate, Jordan, who have no previous diabetes diagnosis. The main questions it aims to answer are: What proportion of participants fall into each Finnish Diabetes Risk Score category? What proportion of participants at high or very high risk have HbA1c results within the prediabetes or diabetes range? Participants will: Complete the Finnish Diabetes Risk Score questionnaire at a community pharmacy. Receive a finger-prick HbA1c test at the pharmacy if their risk score is 15 or higher. Visit a general practitioner or primary care facility for diagnostic confirmation if their HbA1c result is abnormal. Attend follow-up assessments at three and six months if a general practitioner confirms type 2 diabetes.

Key Dates

First listed
Aug 31, 2026
Start date
Oct 1, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2027
Completion
May 31, 2027

Study Design

Enrollment
480 participants (estimated)

Arms

  • Arm: Community Pharmacy Visitors Without Diagnosed Diabetes
    Adults without a previous diabetes diagnosis will complete FINDRISC screening during a community pharmacy visit. Participants with a score of 15 or higher will receive point-of-care HbA1c testing at the community pharmacy. Those with abnormal HbA1c results will be advised to obtain diagnostic confirmation from a general practitioner or primary care facility. Participants with GP-confirmed type 2 diabetes will enter a six-month follow-up period with HbA1c assessments at three and six months. The study will not assign medical treatment.

Primary Outcome Measure

Distribution of Finnish Diabetes Risk Score Categories [ Time Frame: Initial community pharmacy visit on Day 0 ]

Central Contacts

Find similar trials

Nationwide
Type 2 diabetes trialsEndocrinology trialsMetabolic health trialsWeight loss trials

Related Studies